| Document |
Document Title |
|
WO/2024/092361A1 |
There is provided the use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application for wound healing. The thylakoid extract may be used to treat skin or mucosal...
|
|
WO/2024/096825A1 |
The invention is a wound healing composition containing Lucilia sericata larval secretion and cyanobacteria. It contains 63.3-66.66% by weight of Lucilia sericata larval secretion, 31.7-33.33% by weight of cyanobacteria and 5-0.01% by we...
|
|
WO/2024/096418A1 |
The present invention relates to a pharmaceutical or cosmetics composition having anti-inflammatory, anti-pruritic, anti-allergenic, and deodorant effect, the composition comprising composite extract of Lagerstroemia indica and Persicari...
|
|
WO/2024/095232A1 |
A method of performing photodynamic therapy is provided. The method includes applying, to the skin of a patient, a topical composition. The topical composition includes 5- aminolevulinic acid (ALA) hydrochloride, and a vehicle comprising...
|
|
WO/2024/097714A1 |
Methods for treating moderate-to-severe atopic dermatitis of the hand and/or foot in a subject are provided. In one aspect, the methods comprise administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagoni...
|
|
WO/2024/097316A1 |
The present invention relates to methods for treating patients with systemic sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of a soluble guanylate cyclase (sGC) activator of formula (I...
|
|
WO/2024/094841A1 |
Provided herein are methods for Alagille syndrome (ALGS) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing pruritus score, serum bile a...
|
|
WO/2024/094224A2 |
Provided in the present invention are a PBase protein, a fusion protein, a nucleic acid, a gene integration system, a gene delivery system and the use. The PBase protein retains the abilities of binding to the ITR sequences of a Piggybac...
|
|
WO/2024/072942A3 |
One aspect of the present application relates to a pharmaceutical composition comprising a sulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, a skin penetrating agent, where the skin penet...
|
|
WO/2024/096497A1 |
The present invention provides a pharmaceutical composition containing N-nonyldeoxynojirimycin for the suppression, alleviation, or treatment of skin itching; and a cosmetic composition for the suppression, alleviation, or palliation of ...
|
|
WO/2024/093625A1 |
The present invention relates to the technical field of biomedicine. Disclosed is a linolenic acid-derived ceramide, which has a structure of general formula I or an isomer of general formula I: (I), wherein R1 is selected from (II) or (...
|
|
WO/2024/095793A1 |
[Problem] To provide an antioxidant cosmetic. [Solution] Provided is an antioxidant cosmetic containing at least one component selected from the group consisting of (A) a cyclic carboxamide derivative having a specific structure or a sal...
|
|
WO/2024/096692A1 |
The present invention relates to a composition for improving skin condition, containing a Sambucus nigra callus culture or an extract thereof as an active ingredient. The Sambucus nigra callus culture or extract thereof according to the ...
|
|
WO/2024/097606A1 |
The present disclosure relates to certain AHR agonist compounds, for example, having a general formula (I) to pharmaceutical compositions comprising the compounds, and to methods of using the compounds to treat immune-mediated diseases, ...
|
|
WO/2024/093673A1 |
The present application discloses a method for separating a human hair follicle-derived papilla cell. The present application provides a method for separating a hair follicle-derived papilla cell in vitro. The method comprises the follow...
|
|
WO/2024/096401A1 |
One aspect relates to a pharmaceutical composition for wound healing or skin tissue regeneration, the pharmaceutical composition containing an extracellular matrix and a kelp extract. According to one aspect, the extracellular matrix and...
|
|
WO/2024/097290A1 |
This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having an inflammatory skin disease (e.g., erythroderma such as refractory erythroderma). For example, methods and materials that can be ...
|
|
WO/2024/096569A1 |
The present invention relates to a composition, more preferably, a transdermally- or topically-administered composition, comprising, as an active ingredient, a thienopyridine compound of chemical formula 1 or a pharmaceutically acceptabl...
|
|
WO/2024/097836A1 |
Provided herein are assays and methods for identifying which of a plurality of drugs is responsible for causing a delayed-type drug hypersensitivity reaction (dtDHR) in a patient.
|
|
WO/2024/091701A1 |
Provided herein are compositions and methods for tissue repair. In particular, the compositions and methods described herein find use in repairing, regenerating, and modulating fibrosis and inflammation in a variety of tissues such as, f...
|
|
WO/2024/087985A1 |
In order to solve the problems of insufficient heat resistance and insufficient structural strength of an existing natural bactericide microneedle, provided is a microneedle patch for preventing or treating skin infections. The microneed...
|
|
WO/2024/090634A1 |
The present disclosure relates to a composition comprising a K-opioid receptor agonist for preventing, ameliorating, or treating diseases related to skin whitening or pigmentation.
|
|
WO/2024/088395A1 |
Disclosed in the present invention are a series of bridged-ring compounds and a pharmaceutical use thereof, and in particular, disclosed are a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2024/088282A1 |
The present invention provides a pyridazine compound as shown in formula (II), a preparation method therefor, and uses thereof. Also disclosed are uses of the compound of the present invention or the pharmaceutical composition thereof in...
|
|
WO/2024/088175A1 |
Disclosed in the present disclosure are a gRNA targeting VEGFA, a gene editing system, and the use thereof. The gRNA in the present disclosure comprises a guide sequence which has at least 80% sequence identity to any one of SEQ ID NOs: ...
|
|
WO/2024/089076A1 |
The invention relates to a glutamine/tannic acid complex and to a pharmaceutical or cosmetic composition comprising said complex. The present invention also relates to said complex as well as to said composition for use in the prevention...
|
|
WO/2024/091889A1 |
Flt3L is a soluble, focused signal that can expand the dendritic cell compartment. The disclosure provides for methods for regenerating tissue, for preventing wound formation, or for treating wounds in a subject. The methods are achieved...
|
|
WO/2024/091513A1 |
The present disclosure provides polymeric matrices comprising calreticulin (CRbT) and methods of producing and using such matrices. The polymeric matrices are useful in treatment of wounds (e.g., chronic diabetic wound).
|
|
WO/2024/091572A1 |
The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided...
|
|
WO/2024/088110A1 |
Provided are a heterocyclic macrocyclic compound containing an indazole structure and used as a protein kinase inhibitor, and a preparation method therefor. The compound has the structure represented by general formula (I). Additionally ...
|
|
WO/2024/091036A1 |
The present invention relates to a composition for treatment of mitochondrial transplantation for immunomodulation and fibrosis control in multiple sclerosis. The present invention confirmed that, when muscle-derived mitochondria are tra...
|
|
WO/2024/089188A1 |
The invention mainly relates to an active ingredient intended to impart at least a non-therapeutic cosmetic effect, the ingredient comprising an extract consisting of a non-volatile fraction of Canarium exudate, preferably Canarium schwe...
|
|
WO/2024/089495A1 |
The present invention relates to an absorbable composition for the regeneration of skin lesions, comprising chitosan; an organic solvent; metal nanoparticles; resveratrol; taurine; and at least one pharmaceutically acceptable excipient.
|
|
WO/2024/088153A1 |
The use of tropic acid and a derivative thereof in the preparation of a drug for treating psoriasis. It is found that tropic acid and the derivative thereof can significantly improve skin damage of a psoriasis animal model. The tropic ac...
|
|
WO/2024/092047A1 |
Provided herein, inter alia, is a method for treating psoriasis comprising administering an effective amount of pyrrolopyrimidine-based kinase inhibitor of Formula (I).
|
|
WO/2024/091672A1 |
Compositions and methods of preventing, delaying, or ameliorating atopic diseases, such as food allergy, the methods comprising administering a composition having an effective amount of a Bifidobacterium and at least one glycan to an inf...
|
|
WO/2024/089346A1 |
The present invention relates to the non-therapeutic cosmetic use of the peptide of sequence SEQ ID No. 1 and/or its homologues and/or salts and/or derivatives, in particular in the form of rice hydrolysate enriched with said peptide or ...
|
|
WO/2024/090548A1 |
Provided are novel composite materials which contain hydroxyapatite particles and which make it possible to more effectively utilize the activity of the hydroxyapatite particles. An embodiment of the present invention is a hydroxyapatite...
|
|
WO/2024/083856A1 |
The present invention concerns a two-phase formulation comprising (i) a primary powder phase comprising a still alive strain of probiotic bacteria in a freeze-dried state and at least one gelifying agent, and (ii) a complementary aqueous...
|
|
WO/2024/085695A1 |
The present invention relates to a novel altiratinib derivative, a manufacturing method therefor, and a composition comprising same as an active ingredient for the prevention, alleviation, or treatment of skin pigmentation. The altiratin...
|
|
WO/2024/083930A1 |
The invention relates to a topically applied preparation comprising a combination of substances including antimicrobial peptides (AMP), in particular cyclic peptide compounds based on the synthesis of thiazolidine and oxazolidine compone...
|
|
WO/2024/083801A1 |
The invention relates to a foam having a gas phase and an aqueous liquid phase, the gas phase making up at least 50 vol.% of the foam and substantially comprising hydrogen gas, and the aqueous liquid phase comprising at least one dissolv...
|
|
WO/2024/085417A1 |
The present invention relates to a pharmaceutical composition for preventing or treating alopecia areata by acting as a functional inhibitor against S1P receptor subtypes S1PR1 and S1PR4, and, more particularly, to a pharmaceutical compo...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/086100A1 |
Methods and formulations for the systemic protection of an animal from exposure to a photocarcinogen. The methods include orally administering to an animal a formulation comprising a therapeutically effective amount of one or more UV-abs...
|
|
WO/2024/082014A1 |
The present invention relates to compositions comprising cannabidiolic acid and fatty acids; pharmaceuticals, nutraceuticals, medical foods, dietary supplements, functional foods, animal foods and dosage forms comprising this composition...
|
|
WO/2024/082383A1 |
The present invention provides an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody and a use thereof. The monoclonal antibody comprises three heavy chain complementarity determining regions CDR-H1, CDR-H2 and CDR-H3 and th...
|
|
WO/2024/085315A1 |
According to a human fibroblast culture fluid complex (G4PRF-300) effective for regenerating human tissues, a preparation method therefor, and a topical liquid composition containing same, proposed in the present invention, 26 complex gr...
|
|
WO/2024/083176A1 |
Disclosed are the uses of amniotic fluid in the preparation of a drug for treating and/or preventing macrophage-mediated diseases, a drug for treating and/or preventing type M1 macrophage-mediated diseases, a drug for treating and/or pre...
|
|
WO/2024/083210A1 |
Among other things, the present disclosure provides compounds, e.g., of formula I or salts thereof. In some embodiments, the present disclosure provides methods for modulating MRGPRX4 activity. In some embodiments, the present disclosure...
|
